Cytokinetics CYTK AFS Securities
AFS Securities at other companies
Other financials
Where this comes from
Reported directly by Cytokinetics in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent.
The official record: Cytokinetics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Cytokinetics's afs securities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Cytokinetics's AFS securities?
- Cytokinetics (CYTK) reported AFS securities of $254.72M in Q1 2026.
- How has Cytokinetics's AFS securities changed year-over-year?
- Cytokinetics's AFS securities increased by 69.0% year-over-year, from $150.69M to $254.72M.
- What is the long-term trend for Cytokinetics's AFS securities?
- Over 5 years (2020 to 2025), Cytokinetics's AFS securities has grown at a 55.4% compound annual growth rate (CAGR), from $36.95M to $335.05M.
- What does AFS securities mean?
- Long-term financial investments held by the company that are not intended for immediate sale.
- How do you interpret AFS securities?
- An increase reflects capital appreciation or additional investment, while a decrease reflects divestment or market value impairment.
- How does AFS securities compare across companies?
- Varies significantly based on corporate treasury policy; some companies prefer cash, while others diversify into marketable securities.